Fluoxetine prevents dystrophic changes in a zebrafish model of duchenne muscular dystrophy

Human Molecular Genetics

Volumn 23, Issue 17, 2014, Pages 4651-4662

  Waugh, Trent A ^a   Horstick, Eric ^a   Hur, Junguk ^a   Jackson, Samuel W ^a   Davidson, Ann E ^b   Li, Xingli ^a   Dowling, James J ^a,b,c,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BROMOCRIPTINE; DOMPERIDONE; DYSTROPHIN; ERGOTAMINE; FLUNARIZINE; FLUOXETINE; PAROXETINE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SEROTONIN TRANSPORTER; TRANSCRIPTOME; VENLAFAXINE; CALCIUM; EVANS BLUE; MORPHOLINO OLIGONUCLEOTIDE;

ARTICLE; BIREFRINGENCE; CALCIUM HOMEOSTASIS; DISEASE COURSE; DRUG EFFICACY; DRUG SCREENING; DRUG SPECIFICITY; DUCHENNE MUSCULAR DYSTROPHY; EMBRYO; EMBRYO DEVELOPMENT; FOLLOW UP; GENE SILENCING; GENETIC MANIPULATION; MOTOR PERFORMANCE; NONHUMAN; NONSENSE MUTATION; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; SURVIVAL; SYSTEMIC CIRCULATION; TRANSCRIPTOMICS; ZEBRA FISH; ANIMAL; ANIMAL EMBRYO; DISEASE MODEL; DNA MICROARRAY; DRUG EFFECTS; EMBRYOLOGY; GENE EXPRESSION PROFILING; GENETICS; HOMEOSTASIS; MECHANICAL STRESS; METABOLISM; MOLECULAR GENETICS; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BASE SEQUENCE; BIREFRINGENCE; CALCIUM; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DYSTROPHIN; EMBRYO, NONMAMMALIAN; EVANS BLUE; FLUOXETINE; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HOMEOSTASIS; MOLECULAR SEQUENCE DATA; MORPHOLINOS; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STRESS, MECHANICAL; SURVIVAL ANALYSIS; ZEBRAFISH;

EID: 84905647550     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu185     Document Type: Article

References (48)

1. Centers for Disease Control and Prevention (2009) Prevalence of Duchenne/ Becker muscular dystrophy among males aged 5-24 years-four states, 2007. MMWR Morb. Mortal Wkly Rep, 58, 1119-1122.
2. Engel, A. and Franzini-Armstrong, C. (2004) Myology: Basic and Clinical. McGraw-Hill, Medical Pub. Division, New York.
3. Bushby, K., Finkel, R., Birnkrant, D.J., Case, L.E., Clemens, P.R., Cripe, L., Kaul, A., Kinnett, K., McDonald, C., Pandya, S. et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol., 9, 177-189.
4. Verma, S., Anziska, Y. and Cracco, J. (2010) Review of Duchenne muscular dystrophy (DMD) for the pediatricians in the community. Clin. Pediatr. (Phila), 49, 1011-1017.
5. Moxley, R.T. 3rd, Pandya, S., Ciafaloni, E., Fox, D.J. and Campbell, K. (2010) Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J. Child Neurol., 25, 1116-1129.
6. Manzur, A.Y., Kinali,M.and Muntoni, F. (2008) Update on the management of Duchenne muscular dystrophy. Arch Dis. Child., 93, 986-990.
7. Malik, V., Rodino-Klapac, L.R. and Mendell, J.R. (2012) Emerging drugs for Duchenne muscular dystrophy. Expert Opin. Emerg. Drugs, 17, 261-277.
8. Aartsma-Rus, A. (2012) Overview on DMD exon skipping. Methods Mol. Biol., 867, 97-116.
9. Heydemann, A. and McNally, E. (2009) NO more muscle fatigue. J. Clin. Invest., 119, 448-450.
10. Percival, J.M., Adamo, C.M., Beavo, J.A. and Froehner, S.C. (2011) Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the mdx mouse model of Duchenne muscular dystrophy. Handb. Exp. Pharmacol., 323-344.
11. Percival, J.M., Whitehead, N.P., Adams, M.E., Adamo, C.M., Beavo, J.A. and Froehner, S.C. (2012) Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy. J. Pathol., 228, 77-87.
12. Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M.E., Bourke, J., Wells, D.J. et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet, 378, 595-605.
13. Goemans, N.M., Tulinius, M., van den Akker, J.T., Burm, B.E., Ekhart, P.F., Heuvelmans, N., Holling, T., Janson, A.A., Platenburg, G.J., Sipkens, J.A. et al. (2011) Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med., 364, 1513-1522.
14. Banks, G.B. and Chamberlain, J.S. (2008) The value of mammalian models for Duchenne muscular dystrophy in developing therapeutic strategies. Curr. Top. Dev. Biol., 84, 431-453.
15. De Luca, A. (2012) Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview. Acta Myol., 31, 40-47.
16. Zon, L.I. and Peterson, R.T. (2005) In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov., 4, 35-44.
17. Ingham, P.W. (2009) The power of the zebrafish for disease analysis. Hum. Mol. Genet., 18, R107-R112.
18. Bowman, T.V. and Zon, L.I. (2010) Swimming into the future of drug discovery: in vivo chemical screens in zebrafish. ACS Chem. Biol., 5, 159-161.
19. Bassett, D.I., Bryson-Richardson, R.J., Daggett, D.F., Gautier, P., Keenan, D.G. and Currie, P.D. (2003) Dystrophin is required for the formation of stable muscle attachments in the zebrafish embryo. Development, 130, 5851-5860.
20. Kawahara, G., Karpf, J.A., Myers, J.A., Alexander, M.S., Guyon, J.R. and Kunkel, L.M. (2011) Drug screening in a zebrafish model of Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. U S A, 108, 5331-5336.
21. Berger, J., Sztal, T. and Currie, P.D. (2012) Quantification of birefringence readily measures the level of muscle damage in zebrafish. Biochem. Biophys. Res. Commun., 423, 785-788.
22. Winder, S.J., Lipscomb, L., Angela Parkin, C. and Juusola, M. (2011) The proteasomal inhibitor MG132 prevents muscular dystrophy in zebrafish. PLoS Curr., November 17; 3, RRN1286. PMID 22130468.
23. Phillips, M.F. and Quinlivan, R. (2008) Calcium antagonists for Duchenne muscular dystrophy. Cochrane Database Syst. Rev., October 8; 4: CD004571.
24. Kroeze, W.K., Kristiansen, K. and Roth, B.L. (2002) Molecular biology of serotonin receptors structure and function at the molecular level. Curr. Top. Med. Chem., 2, 507-528.
25. Gershon, M.D. (2004) Review article: serotonin receptors and transporters-roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol. Ther., 20(Suppl 7), 3-14.
26. Ramage, A.G. and Villalon, C.M. (2008) 5-Hydroxytryptamine and cardiovascular regulation. Trends Pharmacol. Sci., 29, 472-481.
27. 2+ sensitivity. Br. J. Pharmacol., 127, 740-746.
28. Hajduch, E., Dombrowski, L., Darakhshan, F., Rencurel, F., Marette, A. and Hundal, H.S. (1999) Biochemical localisation of the 5-HT2A (serotonin) receptor in rat skeletal muscle. Biochem. Biophys. Res. Commun., 257, 369-372.
29. Coelho, W.S., Costa, K.C. and Sola-Penna, M. (2007) Serotonin stimulates mouse skeletal muscle 6-phosphofructo-1-kinase through tyrosine-phosphorylation of the enzyme altering its intracellular localization. Mol. Genet. Metab., 92, 364-370.
30. Lek, A., Evesson, F.J., Lemckert, F.A., Redpath, G.M., Lueders, A.K., Turnbull, L., Whitchurch, C.B., North, K.N. and Cooper, S.T. (2013) Calpains, cleaved mini-dysferlinC72, and L-type channels underpin calcium-dependent muscle membrane repair. J. Neurosci., 33, 5085-5094.
31. Mendell, J.R., Engel, W.K. and Derrer, E.C. (1971) Duchenne muscular dystrophy: functional ischemia reproduces its characteristic lesions. Science, 172, 1143-1145.
32. Parker, J.M. and Mendell, J.R. (1974) Proximal myopathy induced by 5-HT-imipramine simulates Duchenne dystrophy. Nature, 247, 103-104.
33. Murphy, D.L., Mendell, J.R. and Engel, W.K. (1973) Serotonin and platelet function in Duchenne muscular dystrophy. Arch. Neurol., 28, 239-242.
34. Arora, R.C., Kuncl, R.W., Morgan, J., Cohen, L. and Meltzer, H.Y. (1987) Serotonin uptake in blood platelets of Duchenne muscular dystrophy patients. Muscle Nerve, 10, 359-362.
35. Saito, F., Blank, M., Schroder, J., Manya, H., Shimizu, T., Campbell, K.P., Endo, T., Mizutani, M., Kroger, S. and Matsumura, K. (2005) Aberrant glycosylation of alpha-dystroglycan causes defective binding of laminin in the muscle of chicken muscular dystrophy. FEBS Lett., 579, 2359-2363.
36. Hudecki, M.S., Pollina, C.M., Bhargava, A.K. and Hudecki, R.S. (1980) Screening of antiserotoninergic drugs with the genetically dystrophic chicken. Arch. Neurol., 37, 545-550.
37. Carre-Pierrat, M., Mariol, M.C., Chambonnier, L., Laugraud, A., Heskia, F., Giacomotto, J. and Segalat, L. (2006) Blocking of striated muscle degeneration by serotonin in C. elegans. J. Muscle Res. Cell Motil., 27, 253-258.
38. Carre-Pierrat, M., Lafoux, A., Tanniou, G., Chambonnier, L., Divet, A., Fougerousse, F., Huchet-Cadiou, C. and Segalat, L. (2011) Pre-clinical study of 21 approved drugs in the mdx mouse. Neuromuscul. Disord., 21, 313-327.
39. Sali, A., Guerron, A.D., Gordish-Dressman, H., Spurney, C.F., Iantorno, M., Hoffman, E.P. and Nagaraju, K. (2012) Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse. PLoS One, 7, e34204.
40. Kaufman, C.K., White, R.M. and Zon, L. (2009) Chemical genetic screening in the zebrafish embryo. Nat. Protoc., 4, 1422-1432.
41. Dowling, J.J., Vreede, A.P., Low, S.E., Gibbs, E.M., Kuwada, J.Y., Bonnemann, C.G. and Feldman, E.L. (2009) Loss of myotubularin function results in T-tubule disorganization in zebrafish and human myotubular myopathy. PLoS Genet., 5, e1000372.
42. Hall, T.E., Bryson-Richardson, R.J., Berger, S., Jacoby, A.S., Cole, N.J., Hollway, G.E., Berger, J. and Currie, P.D. (2007) The zebrafish candyfloss mutant implicates extracellular matrix adhesion failure in laminin alpha2-deficient congenital muscular dystrophy. Proc. Natl. Acad. Sci. U S A, 104, 7092-7097.
43. Dowling, J.J., Arbogast, S., Hur, J., Nelson, D.D., McEvoy, A., Waugh, T., Marty, I., Lunardi, J., Brooks, S.V., Kuwada, J.Y. et al. (2012) Oxidative stress and successful antioxidant treatment in models of RYR1-related myopathy. Brain, 135, 1115-1127.
44. Reich, M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P. and Mesirov, J.P. (2006) GenePattern 2.0. Nat. Genet., 38, 500-501.
45. Dai, M., Wang, P., Boyd, A.D., Kostov, G., Athey, B., Jones, E.G., Bunney, W.E., Myers, R.M., Speed, T.P., Akil, H. et al. (2005) Evolving gene/ transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res., 33, e175.
46. Sartor, M.A., Tomlinson, C.R., Wesselkamper, S.C., Sivaganesan, S., Leikauf, G.D. and Medvedovic, M. (2006) Intensity-based hierarchical Bayes method improves testing for differentially expressed genes in microarray experiments. BMC Bioinformatics, 7, 538.
47. Huang da, W., Sherman, B.T. and Lempicki, R.A. (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res., 37, 1-13.
48. Huang da, W., Sherman, B.T. and Lempicki, R.A. (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc., 4, 44-57.